Harnessing the Potential of CD40 Agonism in Cancer Therapy

Overview

Journal Cytokine Growth Factor Rev

Date 2023 Dec 15

PMID 38102001

Authors

Yang Zhou

Ann Richmond

Chi Yan

Affiliations

Soon will be listed here.

Abstract

CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily of receptors expressed on a variety of cell types. The CD40-CD40L interaction gives rise to many immune events, including the licensing of dendritic cells to activate CD8 effector T cells, as well as the facilitation of B cell activation, proliferation, and differentiation. In malignant cells, the expression of CD40 varies among cancer types, mediating cellular proliferation, apoptosis, survival and the secretion of cytokines and chemokines. Agonistic human anti-CD40 antibodies are emerging as an option for cancer treatment, and early-phase clinical trials explored its monotherapy or combination with radiotherapy, chemotherapy, immune checkpoint blockade, and other immunomodulatory approaches. In this review, we present the current understanding of the mechanism of action for CD40, along with results from the clinical development of agonistic human CD40 antibodies in cancer treatment (selicrelumab, CDX-1140, APX005M, mitazalimab, 2141-V11, SEA-CD40, LVGN7409, and bispecific antibodies). This review also examines the safety profile of CD40 agonists in both preclinical and clinical settings, highlighting optimized dosage levels, potential adverse effects, and strategies to mitigate them.

Citing Articles

Elevated serum CD40 as a potential biomarker for the differential diagnosis of acute thyrotoxic myopathy.

Wu C, Zhang Y, Wang T, Gan M, Qin J, Luo Z Sci Rep. 2025; 15(1):8467.

PMID: 40069315 PMC: 11897197. DOI: 10.1038/s41598-025-93522-3.

First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.

Lakhani N, Stewart D, Richardson D, Dockery L, Van Le L, Call J J Immunother Cancer. 2025; 13(1.

PMID: 39800375 PMC: 11749819. DOI: 10.1136/jitc-2024-010565.

Immune dynamics shaping pre-metastatic and metastatic niches in liver metastases: from molecular mechanisms to therapeutic strategies.

Zhu C, Liao J, Liu Y, Chen Z, Chang R, Chen X Mol Cancer. 2024; 23(1):254.

PMID: 39543660 PMC: 11562679. DOI: 10.1186/s12943-024-02171-z.

GPD1L may inhibit the development of esophageal squamous cell carcinoma through the PI3K/AKT signaling pathway: bioinformatics analysis and experimental exploration.

Gan L, Zhou L, Chu A, Sun C, Wang Y, Yang M Mol Biol Rep. 2024; 51(1):1149.

PMID: 39535578 DOI: 10.1007/s11033-024-10070-1.

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy.

Li C, Yu X, Han X, Lian C, Wang Z, Shao S iScience. 2024; 27(9):110750.

PMID: 39280627 PMC: 11399700. DOI: 10.1016/j.isci.2024.110750.

References

Sarma V, Lin Z, Clark L, Rust B, Tewari M, Noelle R . Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J Biol Chem. 1995; 270(21):12343-6. DOI: 10.1074/jbc.270.21.12343. View

Macatonia S, Hosken N, Litton M, Vieira P, Hsieh C, Culpepper J . Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol. 1995; 154(10):5071-9. View

Schattner E, Elkon K, Yoo D, Tumang J, Krammer P, Crow M . CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med. 1995; 182(5):1557-65. PMC: 2192191. DOI: 10.1084/jem.182.5.1557. View

Wu W, Alexis N, Bromberg P, Jaspers I, Peden D . Mechanisms of LPS-induced CD40 expression in human peripheral blood monocytic cells. Biochem Biophys Res Commun. 2009; 379(2):573-7. PMC: 2649752. DOI: 10.1016/j.bbrc.2008.12.082. View

Donahue A, Fruman D . PI3K signaling controls cell fate at many points in B lymphocyte development and activation. Semin Cell Dev Biol. 2004; 15(2):183-97. DOI: 10.1016/j.semcdb.2003.12.024. View

Sum E, Rapp M, Durr H, Mazumdar A, Romero P, Trumpfheller C . The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation. J Immunother Cancer. 2022; 10(3). PMC: 8928381. DOI: 10.1136/jitc-2021-003264. View

Yan C, Saleh N, Yang J, Nebhan C, Vilgelm A, Reddy E . Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. Mol Cancer. 2021; 20(1):85. PMC: 8182921. DOI: 10.1186/s12943-021-01366-y. View

Pietravalle F, Blasey H, Aubry J, Elson G, Edgerton M, Bonnefoy J . Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem. 1996; 271(11):5965-7. DOI: 10.1074/jbc.271.11.5965. View

von Leoprechting A, van der Bruggen P, Pahl H, Aruffo A, Simon J . Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res. 1999; 59(6):1287-94. View

10.

Stumpp M, Dawson K, Binz H . Beyond Antibodies: The DARPin Drug Platform. BioDrugs. 2020; 34(4):423-433. PMC: 7312107. DOI: 10.1007/s40259-020-00429-8. View

11.

Yan C, Nebhan C, Saleh N, Shattuck-Brandt R, Chen S, Ayers G . Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma. Cancers (Basel). 2023; 15(14). PMC: 10377652. DOI: 10.3390/cancers15143695. View

12.

Liu C, Lewis C, Lou Y, Xu C, Peng W, Yang Y . Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother. 2012; 35(3):276-82. PMC: 3860320. DOI: 10.1097/CJI.0b013e31824e7f43. View

13.

Yacoub D, Benslimane N, Al-Zoobi L, Hassan G, Nadiri A, Mourad W . CD154 is released from T-cells by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17 in a CD40 protein-dependent manner. J Biol Chem. 2013; 288(50):36083-93. PMC: 3861656. DOI: 10.1074/jbc.M113.506220. View

14.

Pham L, Tamayo A, Yoshimura L, Lo P, Terry N, Reid P . A CD40 Signalosome anchored in lipid rafts leads to constitutive activation of NF-kappaB and autonomous cell growth in B cell lymphomas. Immunity. 2002; 16(1):37-50. DOI: 10.1016/s1074-7613(01)00258-8. View

15.

Ishikawa K, Miyamoto M, Yoshioka T, Kato T, Kaji M, Ohbuchi T . Up-regulation of CD40 with juxtacrine activity in human nonsmall lung cancer cells correlates with poor prognosis. Cancer. 2008; 113(3):530-41. DOI: 10.1002/cncr.23618. View

16.

Foss S, Bottermann M, Jonsson A, Sandlie I, James L, Andersen J . TRIM21-From Intracellular Immunity to Therapy. Front Immunol. 2019; 10:2049. PMC: 6722209. DOI: 10.3389/fimmu.2019.02049. View

17.

Funakoshi S, Longo D, Beckwith M, Conley D, Tsarfaty G, Tsarfaty I . Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood. 1994; 83(10):2787-94. View

18.

Yang J, Bergdorf K, Yan C, Luo W, Chen S, Ayers G . CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth. Mol Cancer. 2023; 22(1):92. PMC: 10239119. DOI: 10.1186/s12943-023-01789-9. View

19.

Salomon R, Rotem H, Katzenelenbogen Y, Weiner A, Cohen Saban N, Feferman T . Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting. Nat Cancer. 2022; 3(3):287-302. DOI: 10.1038/s43018-022-00329-6. View

20.

Buhtoiarov I, Lum H, Berke G, Paulnock D, Sondel P, Rakhmilevich A . CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol. 2005; 174(10):6013-22. DOI: 10.4049/jimmunol.174.10.6013. View